EU Biotech Act: What Pharma R&D Professionals need to know - Current status, anticipated changes and what to prepare for now

- Biotech Act: Overview and legislative context - Accelerating clinical trials: What changes? - Regulatory innovation support - Implications for Pharma R&D: A regulatory perspectiveThe EU Biotech Act is still evolving - but preparation cannot wait. Join experts from authority and industry to understand what is coming, what remains uncertain, and how to get your R&D team/organisation ready.LernzieleThe EU Biotech Act is still taking shape. This half-day seminar gives pharma R&D professionals a concise, expert-led overview of the Acts current scope, legislative timeline, and anticipated implications for clinical trial approval procedures, ATMP development, biosimilar pathways, and regulatory innovation tools.- You leave with the insights needed to brief your teams and to shape your strategies ahead of the Acts adoption.ZielgruppenThe seminar addresses professionals in pharma R&D organisations who need to understand and prepare for the EU Biotech Act.It is particularly relevant for those working in biopharmaceutical research and development, including preclinical and clinical settings. A background in drug development, clinical trials, or regulatory affairs is recommended.